Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives $19.79 Consensus Target Price from Analysts

Alphatec Holdings, Inc. (NASDAQ:ATEC) has received an average rating of “Buy” from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $19.79.

A number of equities research analysts recently commented on ATEC shares. Canaccord Genuity upped their target price on Alphatec from $21.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, August 4th. Zacks Investment Research lowered Alphatec from a “hold” rating to a “sell” rating in a report on Tuesday, October 5th. Needham & Company LLC initiated coverage on shares of Alphatec in a report on Wednesday, August 25th. They issued a “buy” rating and a $18.00 price target for the company. Cowen initiated coverage on Alphatec in a research note on Wednesday, August 4th. They set an “outperform” rating and a $22.50 price objective for the company. Finally, Piper Sandler boosted their price target on shares of Alphatec from $19.00 to $22.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 4th.

In related news, major shareholder Jennifer N. Pritzker bought 2,000 shares of the stock in a transaction on Friday, August 27th. The shares were bought at an average cost of $13.26 per share, for a total transaction of $26,520.00. Following the purchase, the insider now owns 38,200 shares of the company’s stock, valued at approximately $506,532. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Scott Lish sold 10,000 shares of the firm’s stock in a transaction on Tuesday, August 3rd. The stock was sold at an average price of $14.24, for a total transaction of $142,400.00. The disclosure for this sale can be found here. Insiders have acquired a total of 5,631 shares of company stock valued at $75,312 in the last quarter. 34.38% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. Ameritas Investment Partners Inc. lifted its stake in shares of Alphatec by 17.0% during the second quarter. Ameritas Investment Partners Inc. now owns 5,397 shares of the medical technology company’s stock valued at $83,000 after buying an additional 785 shares during the period. Altshuler Shaham Ltd grew its position in shares of Alphatec by 103.4% in the first quarter. Altshuler Shaham Ltd now owns 6,223 shares of the medical technology company’s stock valued at $98,000 after purchasing an additional 3,164 shares during the period. O Shaughnessy Asset Management LLC purchased a new stake in Alphatec in the 1st quarter valued at about $118,000. Pinz Capital Management LP purchased a new position in shares of Alphatec during the 1st quarter worth about $129,000. Finally, IFP Advisors Inc boosted its position in shares of Alphatec by 41.8% in the third quarter. IFP Advisors Inc now owns 11,991 shares of the medical technology company’s stock worth $146,000 after acquiring an additional 3,532 shares during the last quarter. Institutional investors and hedge funds own 44.75% of the company’s stock.

Shares of ATEC traded up $0.28 during trading hours on Monday, hitting $12.48. The company had a trading volume of 463 shares, compared to its average volume of 739,086. The company has a market capitalization of $1.25 billion, a PE ratio of -9.84 and a beta of 1.58. The company’s fifty day moving average price is $13.37 and its two-hundred day moving average price is $14.55. Alphatec has a one year low of $8.27 and a one year high of $19.36. The company has a current ratio of 1.92, a quick ratio of 1.11 and a debt-to-equity ratio of 0.26.

Alphatec (NASDAQ:ATEC) last announced its earnings results on Monday, August 2nd. The medical technology company reported ($0.39) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.20). The business had revenue of $62.25 million for the quarter, compared to analysts’ expectations of $51.20 million. Alphatec had a negative return on equity of 86.64% and a negative net margin of 54.09%. Analysts forecast that Alphatec will post -1.13 earnings per share for the current year.

Alphatec Company Profile

Alphatec Holdings, Inc engages in the design, development, and marketing of spinal fusion technology products and solutions for the treatment of spinal disorders. It offers intra-operative information and neuromonitoring technologies, access systems, interbody implants, fixation systems, and various biologics offerings.

See Also: What is the outlook for the FAANG stocks?

Analyst Recommendations for Alphatec (NASDAQ:ATEC)

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with's FREE daily email newsletter.